Oprah Winfrey's recent public appearances have reignited widespread discussion about her noticeable weight loss, with social media users sharing what they describe as 'before and after photos' and questioning whether the media mogul may be using a weight‑loss medication to achieve dramatic results.
While Winfrey has confirmed using a class of drugs known as GLP‑1 medications to assist with weight management, she has not publicly specified a particular brand such as Ozempic.
Images and clips from recent events have circulated across platforms, prompting fans to voice shock and curiosity about her slimmer appearance.
Some commentators have described the transformation as remarkable, fuelling further speculation about the role of medication in her health journey.
Oprah hasaddressed her weight managementpublicly in interviews and onThe Oprah Podcast, where she discussed taking a GLP‑1 weight‑loss medication, a class of drugs that includes Ozempic and Wegovy but without naming the specific product she used.
In these discussions, she reflected on her long‑standing struggle with weight and how the medication altered her relationship with food and hunger cues.
She said that prior to using a GLP‑1 drug she had believed that thinner people simply had more willpower to manage their eating, only to realise that the medication helped reduce intrusive hunger thoughts sometimes referred to as 'food noise'.
Winfrey also shared that she has faced decades of body‑shaming in the public eye and sought to destigmatise the use of medically supervised treatments for obesity and weight management.
Oprah is in favor of Ozempic and similar GLP-1 drugsIn a recent The View appearance, Oprah Winfrey said: "You don't overeat and become obese. It's actually obesity that causes the overeating."pic.twitter.com/wsqf5DRp3J
On social networks, reactions to Winfrey's transformation are mixed. Some fans express admiration for her apparent discipline and new lifestyle, while others voice concern or scepticism about the pace of her weight loss.
Source: International Business Times UK
